Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.
Drug delivery remains a challenge in management of cancer
The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2015-2025 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.
Profiles of 230 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 269 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 12 figures.
Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.
Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Introduction to cancer therapy
2. Innovative treatments for cancer
3. Drug delivery systems for cancer
4. Delivery of Biological Therapies for Cancer
5. Delivery strategies according to cancer type and location
6. Cancer drug delivery markets
7. References
Part II: Companies
8. Companies involved in cancer drug delivery
For more information about this report visit http://www.researchandmarkets.com/research/l7532z/drug_delivery_in
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery, Oncology Drugs


Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 



